The Current Role of Imaging for Prostate Brachytherapy

Overview

Journal Cancer Imaging

Publisher Springer Nature

Specialties Oncology
Radiology

Date 2007 Mar 7

PMID 17339141

Citations 2

Authors

Brendan Carey

Sarah Swift

Affiliations

Soon will be listed here.

Abstract

Prostate brachytherapy is a radiotherapy technique for early stage prostate cancer that uses imaging guidance to place radioactive sources directly into the prostate gland. Transrectal ultrasound is used to facilitate a template-guided transperineal approach to the prostate and permits a highly conformal method of prostate radiotherapy with doses far higher than can be achieved with other radiation techniques. Maturing data has validated this technique as an acceptable treatment option with favourable and durable biochemical outcomes. The radiologist has a major role to play in the process: patient selection, guiding source delivery and follow-up after treatment all require close collaboration with colleagues in Radiation Oncology and Medical Physics. This review emphasises the specific contribution of imaging in the context of currently reported outcomes data.

Citing Articles

Imaging of prostate cancer local recurrences: why and how?.

Rouviere O, Vitry T, Lyonnet D Eur Radiol. 2009; 20(5):1254-66.

PMID: 19921202 DOI: 10.1007/s00330-009-1647-4.

Complications of high intensity focused ultrasound in patients with recurrent and metastatic abdominal tumors.

Li J, Xu G, Gu M, Luo G, Rong Z, Wu P World J Gastroenterol. 2007; 13(19):2747-51.

PMID: 17569147 PMC: 4147127. DOI: 10.3748/wjg.v13.i19.2747.

References

DAmico A, Whittington R, Malkowicz S, Schultz D, Blank K, Broderick G . Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280(11):969-74. DOI: 10.1001/jama.280.11.969. View

RAGDE H, Elgamal A, Snow P, Brandt J, Bartolucci A, Nadir B . Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998; 83(5):989-1001. DOI: 10.1002/(sici)1097-0142(19980901)83:5<989::aid-cncr26>3.0.co;2-q. View

Wallner K, Ellis W, Russell K, Cavanagh W, Blasko J . Use of TRUS to predict pubic arch interference of prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999; 43(3):583-5. DOI: 10.1016/s0360-3016(98)00459-3. View

Merrick G, Butler W, Dorsey A, Lief J, Walbert H, Blatt H . Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1999; 43(5):1021-7. DOI: 10.1016/s0360-3016(98)00486-6. View

Dunn J, Wadghiri Y, Meyerand M . Regional heterogeneity in the brain's response to hypoxia measured using BOLD MR imaging. Magn Reson Med. 1999; 41(4):850-4. DOI: 10.1002/(sici)1522-2594(199904)41:4<850::aid-mrm27>3.0.co;2-l. View

Taussky D, Haider M, McLean M, Yeung I, Williams T, Pearson S . Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy. Brachytherapy. 2004; 3(3):125-9. DOI: 10.1016/j.brachy.2004.06.004. View

Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B . Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int. 2004; 94(9):1235-8. DOI: 10.1111/j.1464-410X.2004.05149.x. View

Xue J, Waterman F, Handler J, Gressen E . Localization of linked 125I seeds in postimplant TRUS images for prostate brachytherapy dosimetry. Int J Radiat Oncol Biol Phys. 2005; 62(3):912-9. DOI: 10.1016/j.ijrobp.2005.02.041. View

Taussky D, Austen L, Toi A, Yeung I, Williams T, Pearson S . Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. Int J Radiat Oncol Biol Phys. 2005; 62(4):974-80. DOI: 10.1016/j.ijrobp.2004.12.012. View

10.

Benoit R, Naslund M, Cohen J . Complications after prostate brachytherapy in the Medicare population. Urology. 2000; 55(1):91-6. DOI: 10.1016/s0090-4295(99)00122-3. View

11.

Padhani A, Gapinski C, Macvicar D, Parker G, Suckling J, Revell P . Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol. 2000; 55(2):99-109. DOI: 10.1053/crad.1999.0327. View

12.

Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J . The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer. Radiother Oncol. 2005; 75(3):303-6. DOI: 10.1016/j.radonc.2005.03.015. View

13.

Tran A, Wallner K, Merrick G, Seeberger J, Armstrong J, Mueller A . Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005; 63(1):150-4. DOI: 10.1016/j.ijrobp.2005.01.021. View

14.

Ciezki J, Reddy C, Garcia J, Angermeier K, Ulchaker J, Mahadevan A . PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys. 2005; 64(2):512-7. DOI: 10.1016/j.ijrobp.2005.07.960. View

15.

Kuban D, Levy L, Potters L, Beyer D, Blasko J, Moran B . Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006; 65(5):1487-93. DOI: 10.1016/j.ijrobp.2006.03.027. View

16.

Charles-Edwards E, deSouza N . Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging. 2006; 6:135-43. PMC: 1693785. DOI: 10.1102/1470-7330.2006.0021. View

17.

Blasko J, Grimm P, Sylvester J, Badiozamani K, Hoak D, Cavanagh W . Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000; 46(4):839-50. DOI: 10.1016/s0360-3016(99)00499-x. View

18.

Merrick G, Butler W, Lief J, Dorsey A . Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000; 47(1):121-8. DOI: 10.1016/s0360-3016(99)00525-8. View

19.

Zelefsky M, Hollister T, Raben A, Matthews S, Wallner K . Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000; 47(5):1261-6. DOI: 10.1016/s0360-3016(00)00550-2. View

20.

Brachman D, Thomas T, Hilbe J, Beyer D . Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000; 48(1):111-7. DOI: 10.1016/s0360-3016(00)00598-8. View